Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab plus unfractionated heparin versus bivalirudin in NSTEMI patients undergoing PCI
2006-002085-19Phase 4Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- May 2006
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Non-ST-segment elevation myocardial infarction (NSTEMI) and acute coronary syndrome (ACS) comparing Abciximab plus unfractionated heparin with Bivalirudin (2 arms). Primary endpoints: Primary composite endpoint and Efficacy composite endpoint. Started May 2006; status: completed.
02
Drugs
abciximabheparinbivalirudin
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2006-002085-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002085-19.